Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huoxue Qiyang Qutan prescription for hypertension with metabolic syndrome
ChiCTR2400081580Phase 3Recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Huoxue Qiyang Qutan in hypertension (HTN) and cardiometabolic risk (CMR) (2 arms), sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoints: Blood pressure and Cardiac ultrasound. Started Mar 2024; status: recruiting.
02
Drugs
Huoxue Qiyang Qutan
03
Conditions
hypertension (HTN)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR2400081580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081580.